RALEIGH, N.C., Oct. 6, 2017 – BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health and Human Services (HHS) to discuss efforts to advance pain management therapies and the treatment of opioid dependence as well as advancing alternative therapies. BDSI was represented by its Vice Chairman, President and Chief Executive Officer, Dr. Mark A. Sirgo, who discussed BDSI’s work to develop novel products, such as buprenorphine, for the treatment of chronic pain and opioid dependence.
“I was pleased to participate in this important discussion convened by HHS, and we appreciate the opportunity to share the work BDSI is doing to advance effective pain management therapies and the treatment of opioid dependence in light of the current opioid epidemic we face,” said Dr. Sirgo. “BDSI has been focused on bringing healthcare providers alternative formulations of buprenorphine based on knowledge that it provides an effective, Schedule III alternative to other more addictive opioids. We recognize the seriousness of the conversation about opioids and their role in pain management in this country and the need to continue to provide and develop effective and safer options for the nearly 100 million Americans who currently suffer from chronic pain as well as those needing support to address their addiction to opioids, and we are pleased to provide products that can be part of the solution.”
During the round table discussion Dr. Sirgo introduced BDSI, highlighted its innovative drug delivery technology and products, and expressed the company’s mission to develop therapies to treat pain as well as opioid dependence.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI’s headquarters is in Raleigh, North Carolina.
For more information, please visit or follow us:
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. ONSOLIS® (fentanyl buccal soluble film) (CII) is licensed in the U.S. to Collegium Pharmaceutical pursuant to the U.S. licensing and development agreement between BDSI and Collegium. For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS, please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentations described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s commercialization programs for BELBUCA and BUNAVAIL) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.
© 2017 BioDelivery Sciences International, Inc. All rights reserved.
SOURCE BioDelivery Sciences International, Inc.